INVO Fertility Q2 Revenue Up 17%, Clinic Platform Turns Profitable
IVF has more than doubled off its 52-week low of $0.9.
Summary
INVO Fertility's Q2 revenue rose 17% to $2.18M and the company swung to a $0.9M net profit, driven by a $2.5M remeasurement gain on the Birmingham acquisition. Clinic-level Adjusted EBITDA reached $333K.
Key Events · Earnings and Guidance · IVF
-
Revenue Up 17%
Q2 2026 revenue was $2,175,485, up from $1,863,654 in Q2 2025, driven by the Family Beginnings acquisition and organic growth.
-
Net Income Swings Positive
Net income was $0.9 million versus a net loss of $3.6 million a year ago, including a $2.5 million gain on remeasurement of the Birmingham acquisition.
-
Clinic Platform Profitable
Clinic-Level Adjusted EBITDA was $333,000 in Q2 2026, up from $164,000 in Q1 2026 and $951,000 for all of 2025.
-
Cash Position
Cash was $3.7 million at June 30, 2026, up from $2.1 million at December 31, 2025.
Analysis · IVF · Industrial Applications And Services
INVO Fertility reported Q2 2026 revenue of $2.18 million, up 17% year-over-year, and swung to net income of $0.9 million from a $3.6 million loss a year ago. The clinic platform generated $333,000 in Adjusted EBITDA before corporate expenses, up from $164,000 in Q1. Cash stood at $3.7 million. The company remains a going concern with a highly dilutive equity line in place, but these results show the core clinic operations are gaining traction.
At the time of this filing, IVF was trading at $2.46 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.90 to $84.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.